Navigation Links
Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
Date:11/30/2011

s. 

The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs.  Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs).  There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs."  Without a known ligand, drug development for a given receptor is extremely difficult.

Omeros uses its proprietary high-throughput CRA to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development.  Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology.  Unlocking these receptors could lead to the development of drugs that act at these new targets. T here is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system.  The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs.  Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market.  Behind its clinical ca
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
2. Omeros to Present at Two Upcoming Conferences
3. Omeros to Present at Future Leaders in the Biotech Industry Conference
4. Omeros to Present at Needham Healthcare Conference
5. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
6. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
7. Omeros Secures $40 Million Committed Equity Financing Facility
8. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
9. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
10. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
11. Omeros Commences Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... July 8 iZumi Bio, Inc. and Pierian, Inc. ... company, iPierian, Inc. Building on the iZumi infrastructure and ... cellular reprogramming to change the paradigm of drug discovery. ... development of new therapeutics using induced pluripotent stem (iPS) ...
... TREK Diagnostic Systems, a Magellan Biosciences business and premier ... labs, has received clearance from the U.S. Food and ... of YeastOne susceptibility products. TREK will make the drug ... the plate that best meets their requirements. The custom ...
... Immunotec Receives NHPD/Health Canada Authorization to Begin a Study on, ... Isolate (Immunocal(R)) in, Combination with Physical Exercise ... Cytokine Levels in Elderly Persons: A Randomized, ... Immunotec Inc. (TSX-V: IMM) announced today that the Natural Health ...
Cached Biology Technology:iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 2iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 3iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 4iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 5iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 6FDA Clears Caspofungin (Cancidas(R)) Susceptibility Testing for TREK Sensititre(R) YeastOne(R) in Vitro Diagnostics (IVD) Product Line 2FDA Clears Caspofungin (Cancidas(R)) Susceptibility Testing for TREK Sensititre(R) YeastOne(R) in Vitro Diagnostics (IVD) Product Line 32009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process 22009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process 3
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... the subway and heading for your destination when you realize ... moment, you feel disoriented, but a scan of landmarks and ... your location, and you make it to your appointment with ... adults, toddlers, rats, chicks and even fish routinely and automatically ...
... EVANSTON, Ill. --- Northwestern University researchers are the first to ... cartilage in vivo and without the use of expensive growth ... cells and produces natural cartilage. No conventional therapy can do ... of Feb. 1 by the Proceedings of the National ...
... how rapidly the Himalayan glaciers are retreating highlights the ... satellites. Since glaciers are among the most reliable ... a major influence on water availability, knowledge of the ... for climate scientists and governing bodies. A key to ...
Cached Biology News:Ability to navigate may be linked to genes, researcher says 2Ability to navigate may be linked to genes, researcher says 3Growing cartilage -- no easy task 2Glacier-melting debate highlights importance of satellites 2
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Biology Products: